Is there resistance to temozolomide in the treatment of glioma?

There is indeed resistance to temozolomide in the treatment of glioma. This phenomenon is one of the common challenges faced by the field of tumor treatment, especially in the treatment of malignant glioma.

Glioma cells may undergo genetic mutations during their growth, and these mutations may change the cells' sensitivity to temozolomide, leading to the development of drug resistance. For example, the promoter methylation status of the MGMT (O^6-methylguanine-DNA methyltransferase) gene is an important factor affecting the efficacy of temozolomide. MGMT promoter methylation can lead to downregulation of MGMT gene expression, thereby enhancing the sensitivity of glioma cells to temozolomide. However, when the MGMT promoter is not methylated, the MGMT gene is expressed normally and can repair DNA damage caused by temozolomide, leading to drug resistance.

Glioma cells may pump out temozolomide by increasing the expression of multidrug resistance proteins (such asP-glycoprotein), reducing the intracellular drug concentration, thereby developing drug resistance.

In addition toMGMT, abnormal activation of other DNA repair pathways (such as homologous recombination repair, non-homologous end joining repair, etc.) may also make glioma cells resistant to temozolomide.

Development of drug resistance

The development of resistance is often gradual and may not be apparent early in treatment but becomes apparent over time. In addition, unreasonable medication regimens (such as too low a dose, too short a medication time, etc.) may also accelerate the development of drug resistance.

For temozolomide-resistant gliomas, temozolomide is often used clinically in combination with other chemotherapy drugs, radiotherapy or targeted therapy drugs to improve the therapeutic effect and delay the development of drug resistance.

Develop an individualized treatment plan based on the patient's genotype and drug resistance mechanism. For example, for patients whose MGMT promoter is not methylated other chemotherapy drugs or targeted therapy drugs may be considered.